Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (4075)	4/16/1998 2:40:00 PM
From: Steve Fancy	Respond to of 6136

Bill, I hear ya. More mad at myself for falling for PW's analyst hype...I know better. I had much higher expectations for forward looking news. You don't get news out of these folks often. I'm watching for March insider sales and will post as available. From what I've heard, the CFO could probably use a little help. Are you familiar with his qualifications? Good luck. sf

To: billkirn who wrote (4075)	4/16/1998 2:45:00 PM
From: Joe E.	Read Replies (1) \| Respond to of 6136

Agouron continues to ramp up sales and profits in line with expectations. Their next drug, though, looks to be a couple of years away, assuming AG3340 makes the cut. So there are not any huge surprises just over the horizon, just the usual slogging. Biotechnology investors love the mystery of the hunt for the silver bullet drug that will cause the stock to triple. Big drug company investors love the steady growth and the broad product lines that give safety and steadily increasing earnings. Agouron is in the misty middle. I think AGPH is worth 45+ and this is another one of those buying opportunities. Better buying opportunities are likely to arise, but this one looks OK. Bill - like your site.